Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EQL Pharma AB ( (SE:EQL) ) has shared an update.
EQL Pharma AB’s Nomination Committee has proposed the re-election of most of its board members, with the exception of Per Ollermark, and the addition of Raymond De Vré as a new board member ahead of the annual general meeting. De Vré brings over 25 years of executive experience in the healthcare and pharmaceutical sectors, potentially strengthening EQL Pharma’s strategic positioning in the generics market.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs. The company focuses on niche generics with limited competition in the Nordic and European markets, particularly in prescription drugs, including hospital products. EQL Pharma AB is based in Lund and is listed on the Nasdaq Stockholm stock market.
YTD Price Performance: 6.17%
Average Trading Volume: 22,324
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.5B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.